Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | ERN1 | O75460 | 15/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | PRKDC | P78527 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5381509 | 0.91 | CRHBP (0.54) | MAPTMEN1POLBKMT2ATDP1 | |
| SCHEMBL7223698 | 0.89 | ERN1 (0.49) | MAPTMEN1POLBKMT2ATDP1 | |
| SCHEMBL30168084 | 0.85 | ERN1 (0.53) | ERN1ALDH1A1CYP3A4ALOX15 | |
| SCHEMBL14392423 | 0.85 | ERN1 (0.47) | MAPTMEN1POLBKMT2ATDP1 | |
| SCHEMBL28961917 | 0.85 | ERN1 (0.53) | ERN1ALDH1A1CYP3A4ALOX15 | |
| SCHEMBL14713554 | 0.85 | ALDH1A1 (0.62) | MAPTMEN1POLBKMT2ATDP1 | |
| SCHEMBL14714242 | 0.85 | MAPT (0.45) | MAPTMEN1POLBKMT2ATDP1 | |
| SCHEMBL14696336 | 0.82 | ERN1 (0.43) | MAPTMEN1POLBKMT2ATDP1 | |
| SCHEMBL14713515 | 0.82 | ERN1 (0.43) | MAPTMEN1POLBKMT2ATDP1 | |
| SCHEMBL12952666 | 0.82 | ERN1 (0.43) | MAPTMEN1POLBKMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8962670-B2 | Anti-cancer agents | UWM RESEARCH FOUNDATION, INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-8637490-B2 | Anti-cancer agents | UWM RESEARCH FOUNDATION, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-20130045949-A1 | ANTI-CANCER AGENTS | UWM RESEARCH FOUNDATION, INC. (US) | 2013-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130045949-A1 | ANTI-CANCER AGENTS | TP53, MCL1, HRAS | MAPT 4804/4885MEN1 3549/4885POLB 650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.